|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6291161B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
GB8918616D0
(en)
|
1989-08-15 |
1989-09-27 |
Univ Glasgow |
Herpes simplex virus type 1 mutant
|
|
ES2061416T3
(es)
|
1990-10-12 |
1997-03-01 |
Max Planck Gesellschaft |
Ribozimas modificadas.
|
|
DE69309472T2
(de)
|
1992-01-23 |
1997-10-23 |
Merck Patent Gmbh, 64293 Darmstadt |
Fusionsproteine von monomeren und dimeren von antikörperfragmenten
|
|
US5652094A
(en)
|
1992-01-31 |
1997-07-29 |
University Of Montreal |
Nucleozymes
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US6972193B1
(en)
|
1993-02-12 |
2005-12-06 |
Board Of Trustees Of Leland Stanford Junior University |
Regulated transcription of targeted genes and other biological events
|
|
EP0804561B1
(en)
|
1993-02-12 |
2009-12-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Regulated transcription of targeted genes and other biological events
|
|
ATE277081T1
(de)
|
1994-01-11 |
2004-10-15 |
Dyax Corp |
Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
GB9415319D0
(en)
|
1994-07-29 |
1994-09-21 |
Medical Res Council |
HSV viral vector
|
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US6093570A
(en)
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
AU8605598A
(en)
|
1997-07-31 |
1999-02-22 |
University Of Pittsburgh |
Targeted hsv vectors
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
JP2002508971A
(ja)
|
1998-01-15 |
2002-03-26 |
アリアド・ジーン・セラピューティクス・インコーポレーテッド |
多量体キメラ蛋白質を使用する生物学的イベントの調節
|
|
JP2002503667A
(ja)
|
1998-02-13 |
2002-02-05 |
プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
新規な二量体化剤、その製造および使用
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
FR2777909B1
(fr)
|
1998-04-24 |
2002-08-02 |
Pasteur Institut |
Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6692736B2
(en)
|
2000-03-24 |
2004-02-17 |
Cell Genesys, Inc. |
Cell-specific adenovirus vectors comprising an internal ribosome entry site
|
|
ATE318923T1
(de)
|
2000-06-01 |
2006-03-15 |
Univ North Carolina |
Doppelsträngige parvovirus-vektoren
|
|
WO2002088346A2
(en)
|
2001-05-01 |
2002-11-07 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
FR2872170B1
(fr)
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
|
JP5136766B2
(ja)
|
2004-12-15 |
2013-02-06 |
ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
キメラベクター
|
|
EP1699826B1
(en)
|
2005-01-05 |
2009-03-11 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
GB0504767D0
(en)
|
2005-03-08 |
2005-04-13 |
Ares Trading Sa |
Lipocalin protein
|
|
EP1829895A1
(en)
|
2006-03-03 |
2007-09-05 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
|
|
WO2010062966A2
(en)
|
2008-11-26 |
2010-06-03 |
The General Hospital Corporation |
Methods for inducing mixed chimerism
|
|
WO2010093784A2
(en)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
EP2524037B1
(en)
|
2010-01-12 |
2018-05-16 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
|
US9169492B2
(en)
|
2010-02-05 |
2015-10-27 |
The University Of North Carolina At Chapel Hill |
Compositions and methods for enhanced parvovirus transduction
|
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
|
US9233125B2
(en)
|
2010-12-14 |
2016-01-12 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
|
|
HUE042040T2
(hu)
|
2012-09-27 |
2019-06-28 |
Merus Nv |
Bispecifikus IGG antitestek mint T-sejt kapcsolók
|
|
DK2956175T3
(da)
|
2013-02-15 |
2017-11-27 |
Univ California |
Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
|
|
WO2014138306A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
CA2904236A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Heparanase expression in t lymphocytes
|
|
EP3925618A1
(en)
|
2013-07-29 |
2021-12-22 |
2seventy bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
ES2857226T3
(es)
*
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
SG10201913782UA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
ES2846881T3
(es)
|
2015-05-01 |
2021-07-30 |
Inhibrx Inc |
Moléculas que se dirigen al sistema de secreción de tipo III
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
EP3341410B1
(en)
|
2015-08-24 |
2021-06-02 |
Cellectis |
Chimeric antigen receptors with integrated controllable functions
|
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
|
JP2019509738A
(ja)
*
|
2016-03-11 |
2019-04-11 |
ブルーバード バイオ， インコーポレイテッド |
ゲノム編集された免疫エフェクター細胞
|
|
EP3443002A4
(en)
|
2016-04-14 |
2019-12-04 |
Bluebird Bio, Inc. |
SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
WO2018127585A1
(en)
*
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
CA3084551A1
(en)
|
2017-12-14 |
2019-06-20 |
Bluebird Bio, Inc. |
Daric interleukin receptors
|
|
SG11202005307RA
(en)
|
2017-12-14 |
2020-07-29 |
Bluebird Bio Inc |
Nkg2d daric receptors
|
|
CN111819682B
(zh)
|
2018-03-26 |
2025-04-29 |
三菱综合材料株式会社 |
绝缘电路基板用接合体的制造方法及绝缘电路基板用接合体
|
|
EP3850013A4
(en)
|
2018-09-10 |
2022-10-05 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
|
|
WO2020113063A1
(en)
|
2018-11-30 |
2020-06-04 |
Aleta Biotherapeutics Inc. |
Single domain antibodies against cll-1
|
|
KR20210104772A
(ko)
|
2018-12-14 |
2021-08-25 |
블루버드 바이오, 인코포레이티드. |
이량체화제로 조절된 면역수용체 복합체
|
|
WO2020123947A1
(en)
|
2018-12-14 |
2020-06-18 |
Bluebird Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US20240034768A1
(en)
|
2018-12-14 |
2024-02-01 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US20240025963A1
(en)
|
2018-12-14 |
2024-01-25 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US20230192805A1
(en)
|
2019-01-14 |
2023-06-22 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric receptor polypeptides and uses thereof
|
|
EP3714941A1
(en)
|
2019-03-27 |
2020-09-30 |
Medigene Immunotherapies GmbH |
Mage-a4 tcrs
|
|
BR112021020999A2
(pt)
|
2019-05-04 |
2021-12-14 |
Inhibrx Inc |
Polipeptídeos de ligação à clec12a e usos dos mesmos
|
|
KR20220031549A
(ko)
|
2019-05-08 |
2022-03-11 |
2세븐티 바이오, 인코포레이티드 |
Cll-1 표적화 면역요법
|
|
MA55910A
(fr)
|
2019-05-08 |
2022-03-16 |
2Seventy Bio Inc |
Immunothérapies ciblant cd123
|
|
EP4004049A1
(en)
|
2019-07-24 |
2022-06-01 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
|
MX2022002984A
(es)
|
2019-09-12 |
2022-06-16 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
|
|
AU2020359530A1
(en)
|
2019-09-30 |
2022-05-19 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US12454580B2
(en)
|
2020-04-10 |
2025-10-28 |
Regeneron Pharmaceuticals, Inc. |
FRB antibodies
|